The business of developing new medicines and bringing them to market has never been more challenging – and there’s no relief in sight. Indeed, the industry is facing what amounts to a financial superstorm over the next 4-5 years. Between evolving policies in play and growing financial pressures, the possibility of significant changes in the business is very real.

Between 2025 and 2030, the pharmaceutical industry is facing a “patent cliff” – loss of exclusivity (LOE) for many of its leading products. That spells the evaporation of between $236 and $400 billion in annual branded drug revenue as generic competition drives prices down.